Q-omics provides the consensus-scored RPL39P18 profile across patient tissues and cancer cell-line models. RPL39P18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL39P18 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RPL39P18 RNA expression shows 7,302 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, KIRC, and TGCT as cancer lineages where RPL39P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39P18 survival associations across molecular data types. RPL39P18 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39P18 RNA expression–survival associations across cancer types. High RPL39P18 expression shows unfavorable associations in KICH, ACC, LGG, KIRC, LIHC and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RPL39P18 RNA expression.
This table summarizes RPL39P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL39P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39P18 shows lower tumor expression in BRCA and higher tumor expression in KIRC, ESCA, CHOL, PRAD and STAD. The KIRC box plot shows higher RPL39P18 RNA expression in tumor versus normal tissue (log2 FC = +0.381, t-test p = .001).
This table shows molecular features associated with RPL39P18 in patient tissues and cancer cell lines. In patient samples, RPL39P18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
